Trexquant Investment’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Trexquant Investment’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-19,503	Closed	-$132K	–	1974
2022 Q1	$132K	Sell	19,503 -29,881	-61%	-$213K	0.01%	1260
2021 Q4	$412K	Buy	+49,384	New	+$407K	0.03%	748
2021 Q3	–	Sell	-33,322	Closed	-$227K	–	1602
2021 Q2	$227K	Buy	+33,322	New	+$277K	0.02%	849
2021 Q1	–	Sell	-24,204	Closed	-$169K	–	1573
2020 Q4	$169K	Buy	+24,204	New	+$188K	0.02%	924
2020 Q1	–	Sell	-68,528	Closed	-$598K	–	1508
2019 Q4	$598K	Buy	+68,528	New	+$370K	0.04%	505
2018 Q4	–	Sell	-33,197	Closed	-$216K	–	1386
2018 Q3	$216K	Buy	+33,197	New	+$247K	0.02%	801

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Trexquant Investment's JNCE Position: Q2 2022 in Review

Trexquant Investment sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 19,503 shares — an estimated $132K sold.

Trexquant Investment first reported a position in JNCE in Q3 2018 and held it in 6 quarters. The position peaked at $598K in Q4 2019. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

Trexquant Investment reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Trexquant Investment sold 19,503 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $132K.
Trexquant Investment first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
Trexquant Investment's Jounce Therapeutics, Inc. Common Stock position peaked at $598K in Q4 2019.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Trexquant Investment's 13F filing for Q2 2022, filed 11 Aug 2022.